NCT00128232View on ClinicalTrials.gov

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

August 31, 2004

Conditions
Acromegaly
Interventions
DRUG

Octreotide LAR

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY